loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Ondansetron

    Client Email Product
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Ondansetron

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    $ API Ref.Price (USD/KG) : 1,225Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    DATA COMPILATION #PharmaFlow

    read-more
    read-more
    The silver lining in Ipca’s Import Alert blues

    The silver lining in Ipca’s Import Alert blues

    Ipca Laboratories finished dosage facilities at Silvasa and Pithampur (India) were put on the FDA Import Alert List this week, an outcome of Ipca running into problems in yet another FDA inspection. The latest alert comes after Ipca’s API facility in Ratlam (India) was banned from exporting to the U.S. in January this year. However, when reviewing the details of Ipca’s alert, is there a business opportunity which can be capitalized upon? The FDA Import Alert, while banning all imports from the Pithampur facility, has stopped everything coming out of the Silvasa plant except Hydroxychloroquine Sulfate & Propranolol Hydrochloride. Ipca’s Ratlam facility had received a similar exemption earlier for the following APIs: Sulfamethoxazole, Trimethoprim, Ondansetron, Hydroxychloroquine Sulfate, Propranolol Hydrochloride and Furosemide. Given all the details that have been published about the observations at Ipca’s various facilities, a complete shutdown of all imports into the U.S. would have been expected.   Why did a few of Ipca’s products get an FDA import alert exemption? Business Standard reported, at the time of covering the initial Ratlam ban that “Given the acute shortage in the US, the FDA, however, has exempted four APIs from the import ban.” The article also mentions the market growth of Hydroxychloroquine from $30 million to $120 million in the last few years. While the FDA hasn’t yet put Hydroxychloroquine on their drug shortage list, concerns regarding supply disruption are already being felt. Wyeth’s branded Propranolol Hydrochloride was a $215 million product in 2006, before intense generic competition reduced the market to about 10% of its original size in less than two years. While almost every major generic company has some variant of Propranolol Hydrochloride on the market, the number of API suppliers are extremely limited. Pharma Compass’ database shows that as Ipca, Albemarle (USA) and Cosmo Spa (Italy) are the only active Drug Master Files in the FDA database, capacity expansion constraints in Europe and United States could provide an opportunity for compliant API manufacturing of Propranolol Hydrochloride.  With API manufacturers looking for new horizons, Ipca’s exemptions of old products like Sulfamethoxazole, Trimethoprim, Ondansetron, Hydroxychloroquine Sulfate, Propranolol Hydrochloride and Furosemide should provide an manufacturing and marketing opportunity worth examining. Search our database for Sulfamethoxazole, Trimethoprim, Ondansetron, Hydroxychloroquine Sulfate, Propranolol Hydrochloride and Furosemide to study the competitive landscape of manufacturers, pricing information and a lot more. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 4315

    https://www.pharmacompass.com/radio-compass-blog/the-silver-lining-in-ipca-s-import-alert-blues

    #Phispers by PHARMACOMPASS
    27 Mar 2015
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Adial Pharma Announces Journal Publication Supporting AD04 For Alcohol Disorder
    Adial Pharma Announces Journal Publication Supporting AD04 For Alcohol Disorder

    20 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/20/2901669/26135/en/Adial-Pharmaceuticals-Announces-Publication-in-Leading-Peer-Reviewed-Journal-Supporting-the-Potential-Efficacy-of-AD04-as-a-Precision-Medicine-for-the-Treatment-of-Alcohol-Use-Diso.html

    GLOBENEWSWIRE
    20 Jun 2024
    Share Share
    Health Canada Issues Recalls of Accel Pharma's Ondansetron
    Health Canada Issues Recalls of Accel Pharma's Ondansetron

    06 Jun 2024

    // HEALTH CANADA

    https://recalls-rappels.canada.ca/en/alert-recall/accel-ondansetron-odt-4-8-mg-data-integrity-concerns-product-s-bioequivalence-data

    HEALTH CANADA
    06 Jun 2024
    Share Share
    Enforcement Report - Week of December 13, 2023
    Enforcement Report - Week of December 13, 2023

    13 Dec 2023

    // FDA

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-december-13-2023-38736.pdf

    FDA
    13 Dec 2023
    Share Share
    RedHill's RHB-102 (BEKINDA®) & Opaganib Granted New Patents in Oncology Setting
    RedHill's RHB-102 (BEKINDA®) & Opaganib Granted New Patents in Oncology Setting

    01 May 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/redhills-rhb-102-bekinda-and-opaganib-granted-new-patents-in-oncology-setting-301811839.html

    PR NEWSWIRE
    01 May 2023
    Share Share
    Enforcement Report - Week of February 22, 2023
    Enforcement Report - Week of February 22, 2023

    22 Feb 2023

    // FDA

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-february-22-2023-51785.pdf

    FDA
    22 Feb 2023
    Share Share
    Heron scores FDA for Aponvie, alternative to pills for postoperative nausea
    Heron scores FDA for Aponvie, alternative to pills for postoperative nausea

    20 Sep 2022

    // Kevin Dunleavy FIERCEPHARMA

    https://www.fiercepharma.com/pharma/heron-scores-fda-go-ahead-aponvie-iv-alternative-pills-postoperative-nausea

    Kevin Dunleavy FIERCEPHARMA
    20 Sep 2022
    Share Share